OptiBiotix获得欧洲对其重量管理补充品的主要订单,定于2026年初发射。 OptiBiotix secured a major European order for its weight-management supplements, set for launch in early 2026.

Optibiotix Health PLC股份在获得第一个商业订单后上升了7.4%。 该公司的SlimBiome和WellBiome产品的私人标签版的欧洲重量管理品牌为第一个商业订单,预计将在2026年初推出。 OptiBiotix Health PLC shares rose 7.4% after securing its first commercial order from a major European weight-management brand for private-label versions of its SlimBiome and WellBiome products, with the launch expected in early 2026. 这项“低六位数”协议标志着八月协议中的一个重要里程碑，反映了对类似GLP-1药物的天然食欲抑制补充剂需求的增长。 The "low six-figure" deal marks a key milestone under an August agreement and reflects growing demand for natural appetite-reducing supplements similar to GLP-1 drugs. 该公司引用了强有力的临床数据和与全球品牌的伙伴关系,如Hydrexycuter、Morepen博士的灯光生命和Holland & Barrett等,作为推动势头的动力,预计2026年将进一步开发产品。 The company cited strong clinical data and partnerships with global brands like Hydroxycut, Dr Morepen’s LightLife, and Holland & Barrett as drivers of momentum, with further product developments expected in 2026.